Bronconex Acticap

Valsts: Jaunzēlande

Valoda: angļu

Klimata pārmaiņas: Medsafe (Medicines Safety Authority)

Aktīvā sastāvdaļa:

Mometasone furoate 400ug (anhydrous)

Pieejams no:

Organon (New Zealand) Limited

SNN (starptautisko nepatentēto nosaukumu):

Mometasone furoate 400 µg (anhydrous)

Deva:

400 mcg/dose

Zāļu forma:

Powder for inhalation

Kompozīcija:

Active: Mometasone furoate 400ug (anhydrous) Excipient: Lactose

Vienības iepakojumā:

Inhaler, metered, DPI, (sample), 14 dose units

Klase:

Prescription

Receptes veids:

Prescription

Ražojis:

MSD International GmbH (Singapore Branch)

Ārstēšanas norādes:

Bronconex Acticap is indicated for prophylactic therapy in the management of patients with asthma of all severities, including patients who have been dependent upon either inhaled or systemically administered corticosteroids and non-corticosteroid-dependent patients inadequately controlled on other drug regimens.

Produktu pārskats:

Package - Contents - Shelf Life: Inhaler, metered, DPI, (sample) - 14 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 30 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 60 dose units - 18 months from date of manufacture stored at or below 25°C

Autorizācija datums:

2000-12-05